NEW YORK, Nov. 17 (GenomeWeb News) - Shares in Ciphergen tumbled 13.87 percent, or $.24, to $1.49 in mid-afternoon trading after Ciphergen yesterday said that its second-quarter earnings report should "no longer be relied upon."


To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.